Vetfar Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 02-11-2024
- Paid Up Capital ₹ 9.99 Cr
as on 02-11-2024
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 17.60 Cr
as on 02-11-2024
- Revenue %
(FY 2023)
- Profit -16.00%
(FY 2023)
- Ebitda -25.00%
(FY 2023)
- Net Worth 9.12%
(FY 2023)
- Total Assets 122.28%
(FY 2023)
About Vetfar Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.99 Cr.
The company currently has active open charges totaling ₹17.60 Cr.
Rahul Nachane and Rajesh Lawande serve as directors at the Company.
- CIN/LLPIN
U24299MH2021PTC366147
- Company No.
366147
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Aug 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vetfar Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Lawande  | Director | 21-Aug-2021 | Current |
| Rahul Nachane | Director | 21-Aug-2021 | Current |
Financial Performance and Corporate Structure Insights of Vetfar Pharmaceuticals.
Vetfar Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 16% decrease in profit. The company's net worth moved up by a moderate rise of 9.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vetfar Pharmaceuticals?
In 2023, Vetfar Pharmaceuticals had a promoter holding of 93.49% and a public holding of 6.51%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Macrotech Polychem Private LimitedActive 20 years 9 monthsRahul Nachane and Rajesh Lawande are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 16 Jan 2023 | ₹17.60 Cr | Open |
How Many Employees Work at Vetfar Pharmaceuticals?
Vetfar Pharmaceuticals has a workforce of 0 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vetfar Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vetfar Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
